Shepherd Street Advisors LLC Invests $534,000 in Gilead Sciences, Inc. $GILD

Shepherd Street Advisors LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 4,352 shares of the biopharmaceutical company’s stock, valued at approximately $534,000.

A number of other hedge funds have also modified their holdings of GILD. Brighton Jones LLC increased its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences in the fourth quarter worth $215,000. Sivia Capital Partners LLC increased its stake in shares of Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 602 shares during the last quarter. Ieq Capital LLC increased its stake in shares of Gilead Sciences by 12.0% in the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock worth $13,160,000 after acquiring an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its stake in shares of Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after acquiring an additional 674 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research reports. Wall Street Zen downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a research report on Wednesday, May 20th. Daiwa Securities Group decreased their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Morgan Stanley decreased their price target on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Finally, Truist Financial reiterated a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Twenty-six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis, showing statistically significant ALP normalization versus placebo after 52 weeks. This adds to investor optimism around its liver disease franchise and broader growth prospects. Article Title
• Positive Sentiment: Separate coverage highlighted additional favorable Livdelzi data, including long-term efficacy and safety findings and a post hoc analysis showing sustained normalization of a key liver marker in PBC patients. These results reinforce confidence in the drug’s commercial potential. Article Title Article Title
• Positive Sentiment: Royal Bank of Canada upgraded Gilead from hold to moderate buy, which can bolster sentiment by signaling improved analyst confidence in the stock’s outlook.
• Positive Sentiment: Cencora announced it will support U.S. distribution of Kite’s FDA-approved CAR-T therapies, Yescarta and Tecartus, helping ensure continued commercialization and access for an important Gilead unit. Article Title
• Neutral Sentiment: Gilead also has several upcoming and recent oncology presentations with Kite at ASCO and EHA, which keep the company in focus but do not yet provide a clear near-term financial read-through. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title

Insider Activity

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 68,000 shares of company stock valued at $9,047,570. 0.30% of the stock is owned by insiders.

Gilead Sciences Stock Performance

GILD opened at $127.57 on Wednesday. The company has a market cap of $158.39 billion, a PE ratio of 17.38 and a beta of 0.31. The stock has a 50-day moving average of $135.10 and a 200-day moving average of $134.26. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.